Warren Buffett's Berkshire Hathaway was doing more selling than buying of stocks during the second quarter, but there is one new holding: New Jersey-based medical technology company Becton Dickinson. Berkshire also added to its stake in Johnson & Johnson, although the holdings are still well below where they were before Buffett sold over 33 million shares last fall.
Retailers reported disappointing sales in July, a sign that consumers are continuing to watch their spending carefully and hunting for the best bargains.
Analysts are expecting a late start to the back-to-school shopping season, and that means that retail sales reports for July, which are due out Thursday morning, will likely be weak.
Cramer makes the call on viewers' favorite stocks.
Friday I got to dress up my basset hound, Homer, in a new, as-yet-to-be-released, beach knapsack made especially for dogs by Body Glove.....Pet products and services are a $40 billion business in the U.S. which may be recession-proof, so everybody would like to dive in.
Merchants across the nation have spent years unsuccessfully fighting interchange fees, which generates an estimated $40 billion to $50 billion in income annually for banks that issue credit cards. But after Congress passed a law last month to protect consumers from excessive fees and interest on credit cards, merchants are mounting a fresh offensive.
Earnings season may have "officially" gotten underway with last week's release by Dow component Alcoa, but it kicks into full gear Tuesday with two very significant pre-market releases: quarterly numbers from Goldman Sachs and Dow stock Johnson & Johnson.
Warren Buffett spoke tonight (Thursday) on tape with CNBC's Julia Boorstin at Herb Allen's Sun Valley media conference. He remains pessimistic about the economy's short-term prospects, saying the latest number from his Berkshire Hathaway companies show that consumer spending remains very weak. This is a video clip and transcript of Julia's entire conversation with Buffett.
Stocks squeaked out another gain Thursday as investors were encouraged by Alcoa's beat and a drop in jobless claims but pharmaceutical and retail stocks dragged.
Stock futures are up modestly on better-than-expected jobless claims data and Alcoa’s smaller-than-expected loss.
Stocks opened higher Thursday as jobless claims dropped below a key level and Dow component Alcoa kicked off earnings season with a beat.
Futures indicated a rebound for Wall Street on Thursday as jobless claims dropped below a key level and Dow component Alcoa started the earnings season beating expectations.
Following are the day’s biggest winners and losers. Find out why shares of Family Dollar and Peabody Energy popped while Advanced Micro Devices and Aetna dropped.
After months of wondering whether the recovery is for real, investors may get the chance to find out when second-quarter earnings start rolling in.
The second half of 2009 kicked off with a bang with both the Dow and S&P trading higher after reports showed manufacturing began improving, albeit modestly.
Two days after the FDA ordered Matrixx Initiatives' Zicam off the market the story remains one of the most emailed articles on "The New York Times" website. And the company seems to still be trying to find its corporate crisis footing.
I was an early adopter of Zicam when it came on the market 10 years ago. Whenever I felt a cold coming on, I'd load up on the stuff along with Vitamin C and zinc lozenges. So, last night I went searching through the bathroom cabinets to find my Zicam stash to toss it in the trash per the FDA's advisory.
Whole Foods has dropped more than 13 percent in the last week, but that isn't stopping traders from stepping in to buy upside options.
I have a confession to make. I try to be as transparent as possible, to share as much information as I can about how the sausage is made. To that end, on at least a few occasions I’ve mentioned on this blog and on CNBC, that I’ve been on 10 milligrams of Lipitor.
Wal-Mart Stores announced a new $15 billion share repurchase program and said it'll increase its fiscal-year dividend by 15 percent, to $1.09 per share. Should you buy it? John Lawrence, managing director of equity research at Morgan Keegan, offered CNBC his investment advice.